Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
US Patent Number
9,567,585
Publication Date
2-14-2017
Abstract
The present invention provides, among other things, oligonucleotide modulators of human 5'-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.
Assignees
Shire Human Genetic Therapies, Inc., Lexington, MA (US); University of Kentucky, Lexington, KY (US)
Application Number
14/357,388
Filing Date
11-9-2012
Recommended Citation
Stamm, Stefan; Shen, Manli; and Josiah, Serene, "Antisense Oligonucleotide Modulators of Serotonin Receptor 2C and Uses Thereof" (2017). Molecular and Cellular Biochemistry Faculty Patents. 23.
https://uknowledge.uky.edu/biochem_patents/23
